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INTRODUCTION 
All living organisms exist as a product of reproduction; it is one of the most crucial 
features of life. The inherent desire to reproduce, create offspring, and pass on genetic 
information regulates much of the behavior of all animals.1 Without reproduction, life could not 
continue. Such a large and important topic garners incredible interest. In humans, the interest 
leads to a desire to achieve a complete understanding of and control over the process.  
Control of reproduction strengthens methods of family planning. Family planning gives 
individuals the ability to decide and regulate when they reproduce. The use of contraception, or 
birth control, is integral in this process to temporarily prevent reproduction when intended. 
Contraception is the method of preventing pregnancy using medications or devices.2 The 
improvement in the quality of contraceptives and their increased widespread availability over the 
last half of a century allowed for many cultural and social changes to occur. With appropriate 
care providers, more women became more informed decision makers regarding their 
reproductive health. This vast acquired knowledge and increased access to safe and effective 
contraceptives played a role in empowering women to pursue higher education, compete for high 
ranking jobs, and decide when they chose to bear children.3  
The contraceptive industry has exploded since its inception in the 1960s. Each year more 
women, of child bearing age, seek out a form of contraception. However, many hormonal and 
non-hormonal products do not work effectively for each user. Consequently, research to create 
multiple high quality contraceptives has been consistent for decades. Many women cite these 
products as life changing due to the control they provide over reproduction and the reduction of 
symptoms of various health conditions. 4 Extensive research has pushed past the standard birth 
control pill and led to the creation of combination pills, non-hormonal options, and devices, both 
	 	
	
Madden 3 
temporary and permanent. Current research in the industry is evolving to create more non-
hormonal options and explore the possibility of a contraceptive combined with an antiretroviral 
to protect against sexually transmitted diseases. 4  
While contraceptives still provide those benefits of freedom and control to women today, 
they are also used to treat the symptoms of reproductive related hormonal imbalances. Many 
young women are prescribed a combination oral contraceptive pill to manage acne, ovarian 
cysts, and irregular menstrual cycles. These treatments are exogenous hormones in the form of 
contraceptives to alleviate painful symptoms, improve confidence, and more. Researchers at 
Penn State/Hershey Medical Center found combination oral contraceptive pills to be safe and 
effect for the treatment of acne in females. 5 They conducted a review by analyzing various valid 
clinical trials for safety and efficacy. The findings were used in conjunction with physiological 
explanations to draw a conclusion supporting the continued use of contraceptives for treatment 
of acne. 5 
Control of reproductive health and family planning is a spectrum. Like other 
physiological processes, there can be too much activity leading to a need to suppress it or not 
enough creating a need to upregulate it. The latter applies to the reproductive system when 
conception is intended but not achieved. Medications and treatments within the scope of 
reproductive health also include those that increase reproductive potential. Infertility is defined 
as the failure to achieve clinical pregnancy after 12 months. This disorder of the reproductive 
system effects over 12% of women, aged 15-44, in the United States. 6 The cause of infertility 
varies from patient to patient, contributing factors can be genetic, epigenetic, or unexplained, and 
both men and women can be affected. 2 Solving the puzzle of infertility requires extensive study 
into all components of the female and male reproductive systems. All anatomical and endocrine, 
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or hormonal, factors must be well understood to achieve the safest treatments and best outcomes. 
Infertility treatments typically focus on gonadotropin hormone levels as predictors of 
reproductive capacity and as potential modes of treatment. Procedural treatments such as in vitro 
fertilization (IVF) and intrauterine insemination (IUI) are both frequently preceded by a regimen 
of exogenous reproductive hormones, or gonadotropins. The exogenous hormone is used to 
increase the number of mature follicles in the ovarian reserve and to prepare the body to be more 
fertile, if hormonal imbalances exist. 7 The gonadotropins, and more recently developed 
recombinant gonadotropins, are consequently a crucial component to successful fertility 
treatments and interventions. All 
components of gonadotropin signaling 
pathways have the potential to play a 
role in the correct execution of their 
functions. Therefore it is important to 
focus research on all levels in the 
pathway to fully understand why 
something may be going wrong.  
The physiology of reproduction 
in men and women is controlled by 
many hormones of the endocrine 
system, two of which are gonadotropins 
called follicle stimulating hormone (FSH) 
and luteinizing hormone (LH).  The two 
gonadotropins are peptide hormones that 
Figure 1. Map of the HPG Axis, showing the origins 
and target tissues of some of the gonadotropin 
hormones of the reproductive endocrine system.   
Koopman, P. 2013. 
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are part of the hypothalamic – pituitary – gonadal (HPG) axis. 8 When activated, the 
hypothalamus releases gonadotropin releasing hormone (GnRH) which travels through the 
hypothalamic portal system to the anterior pituitary. The presence of GnRH in the anterior 
pituitary stimulates the release of gonadotropins, FSH and LH, into the blood stream to act on 
target tissues: the Sertoli cells of testes in men and the granulosa cells of ovaries in women. 
These hormones are at the center of reproductive pathways in women and men and consequently 
are of high interest in reproductive research. 8 
Human follicle stimulating hormone (hFSH) is a peptide hormone classified as a 
gonadotropin and is released during the follicular phase of the female menstrual cycle. 9 hFSH 
mediates the maturation of gametes in both females (oogenesis) and males (spermatogenesis). It 
is a 35.5 kDa heterodimer, consisting of an alpha and a beta subunit. The alpha subunit is 
identical to that of LH. The beta subunit is unique to FSH and therefore is required for proper 
function and signaling. HFSH works by binding to hFSH receptors on the target cell membranes 
to initiate a signal transduction. 9 
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HFSH cannot generate the signal transduction for these 
reproductive processes if its receptor (hFSHR) is not present or 
is not functioning. HFSHR is a g protein-coupled receptor 
(GPCR). GPCRs are embedded in the cell membrane, with some 
regions reaching outside of the cell to bind and receive stimuli 
and others located inside the cell and cell membrane to excite 
the signal transduction pathway. The receptor is a 76 kDa 
protein with three main domains. The extracellular domain is 
responsible for hormone binding. The transmembrane domain is 
made up of seven transmembrane alpha helices and makes up 
most of the physical receptor. The C-terminal domain is 
intracellular and responsible for interacting with the g-protein 
that will become activated to transmit and execute changes in 
signaling. HFSHR is a specific receptor, activated only by 
hFSH, though GPCRs in general are quite abundant. 10 
Cell membranes are incredibly heterogeneous, consisting of many molecules like 
cholesterol, glycoproteins, and transmembrane proteins like hFSHR embedded within the lipid 
bilayer. 11 hFSHR has been shown to be located within compartments of the cell membrane 
known as lipid rafts. 12 Lipid rafts are microdomains of the membrane containing a higher 
concentration of cholesterol, glycosphingolipids, and a protein called caveolin. Rafts are tightly 
packed and more ordered than the rest of the lipid bilayer. The high concentration of important 
membrane proteins and cholesterol allow lipid rafts to become crucial organizing and regulating 
centers for cell signaling molecules like GPCRs. These unique microdomains are believed to 
Figure 2. Ribbon structure 
of hFSH. Alpha subunit 
colored in grey, beta 
subunit shown in black.     
(Dias, et al. 2002) 
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play a role in cellular signal transduction pathways and membrane trafficking. It is also thought 
that the rafts serve to protect the signaling molecules from other membrane disruptors or 
enzymes. 13 Many GPCRs, including hFSHR, are thought to reside within lipid rafts. Previous 
research in the Cohen Laboratory at Union College has demonstrated that hFSHR is located 
within lipid rafts.  
 
 
Caveolin is a membrane protein found within lipid rafts. Microdomains of the cell 
membrane that are rich in caveolin are a subset of lipid rafts called caveolae. These specific 
regions often take on an indentation, or U-shaped invagination, of the plasma membrane. 
Caveolin interacts with hFSHR, although the specific location and the physiological relevance of 
the interaction are still unclear. 14 Researchers speculate that caveolin acts to anchor GPCRs 
within lipid rafts to improve signaling. Based on homology with other proteins, the most likely 
Figure 3. Schematic of the phospholipid bilayer, contrasting a lipid raft and a non-raft 
area. 
Villar, VAM, et al. 2016.  
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site of interaction with caveolin is 
a portion of the hFSHR protein 
found in the fourth 
transmembrane region. The region 
contains a specific ten amino acid 
sequence shared by other proteins 
that interact with caveolin and it is 
known as a caveolin interaction 
motif (CIM) (circled in red, 
Figure 4). 9    
We hypothesize that the 
interaction between hFSHR and caveolin regulates the FSH signaling pathway in some way. 
Further, we are interested in gathering more evidence pertaining to hFSHR lipid raft residency 
and investigating alterations in receptor residency. We will attempt to evaluate receptor location, 
with respect to membrane rafts, under time dependent exposures to hFSH, using discontinuous 
sucrose gradients. We will also explore the role of caveolin interaction motif (CIM) memetic 
peptides, both wild type and mutant, and the effects they may have on receptor residency. We are 
interested in studying receptor residency and the interaction with caveolin because it has the 
potential to introduce new ways to modulate the receptor. Increased control over the receptor 
could allow for further investigation into improved contraception methods and infertility 
treatments that could alter this physiological pathway without requiring exogenous hormone.  
 
 
Figure 4. Schematic of hFSHR transmembrane 
domains, including its sequence. Circled in red is the 
caveolin binding motif. 
Dias, JA, et al. 2002. 
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METHODS 
Human embryonic kidney 293 (HEK293) cells were stably transfected to express human 
follicle stimulating hormone receptor. The cells were grown and incubated in tissue culture in 
G418 media. This stable cell line was used in all experiments.  
 
Time Dependent Hormone Treatment 
1. Hormone Treatment  
 Four T75’s of HEK293R cells were used, one for each varying timed exposure to hFSH. 
The G418 media (18 mL) was removed from all T75’s and replaced with Serum Free media (5 
mL) for 1 hour. Human urinary hFSH was used for all treatments. 4 uL hFSH was added to 1mL 
Serum Free media. The cells were spiked with hormone using this diluted mix (250 uL). The 
cells were exposed to hFSH for 0, 5, 15, or 30 minutes. All samples were placed on ice 
immediately following the expiration of the assigned amount of exposure.  
2. Discontinuous Sucrose Gradients 
 Discontinuous Sucrose Gradient is a differential centrifugation technique used to separate 
cell parts by density. Sucrose is layered to create a density gradient to allow for buoyant (less 
dense) lipid raft membranes to be differentiated from other cellular membranes.  
 At the completion of the respective hormone time courses, all media was removed from 
the four T75’s. All cells were then washed with 1X PBS (5 mL) and harvested from the T75’s 
using 5 mM EDTA/1X PBS (5mL). The four samples (0, 5, 15, 30) of harvested cells were 
centrifuged at 4400rpm for 10 minutes, to separate them from the harvesting solution. The 
supernatant liquid was removed and the cells were resuspended in 0.5 M sodium carbonate (pH 
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11; 0.75 mL). The samples were left on ice for 20 minutes. They were then sonicated three times 
for 10 seconds to disrupt the cell membranes.  
The sonicated samples were mixed with 0.75mL of 90% sucrose in 1X MBS. This 
mixture then was added to ultracentrifuge tubes. 35% sucrose in 0.5xMBS and 0.25M Na2CO3  
(~1.5 mL) was layered dropwise on top of the 90% sucrose + sample mixture, using a syringe 
and hypodermic needle. By the same technique, 5% sucrose in 0.5xMBS and 0.25M Na2CO3 
(~1.5 mL) was layered on top up to the neck of the tube. Samples were then centrifuged in an 
SW41 rotor at 34,000rpm (240,000G) for 20 hours.  
 After 20 hours of ultracentrifugation, the samples were each broken down into fractions 
from the top of the ultracentrifuge tube to the bottom. 8-12 fractions were created per sample. 
This method keeps the density gradient intact by the order of fractions, to be used for comparison 
and analysis.  
3. Western Blot Analysis 
SDS Polyacrylamide Gel Electrophoresis was used to separate proteins and identify the 
presence of hFSHR for qualitative analysis. 10% acrylamide gels were cast and loaded with the 
sample fractions in order of the density gradient. The first sample loaded farthest to the right 
corresponded with the top of the gradient, or the first fraction taken off. All four gels were run 
and transferred to Immuno-Blot membranes for western blotting and chemiluminescent imaging.  
Western blotting, or immunoblotting, is a technique used to visualize and image proteins 
separated by SDS-PAGE for identification and qualitative analysis. The technique allows for the 
identification of hFSHR in each sample fraction. Specifically, it is also useful for qualitative 
comparison of alterations of hFSHR lipid raft residency by using differences in band darkness as 
a proxy for comparisons of receptor concentrations between samples.  
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 The gels were transferred to Immuno-Blot membranes using 1X transfer buffer and a 
transferring instrument, at 15V for 15 minutes. The membranes were then blocked in 5% milk in 
TBST (10 mL) for an hour at room temperature. Next, the membranes were incubated in an anti-
hFSHR monoclonal antibody, 105 (5 uL) in 5% milk in TBST (10 mL), overnight at 4 degrees C. 
The membranes were then washed for 5 minutes, three times each, in 1X TBST. Then 
membranes were incubated in the secondary antibody, goat anti-mouse (5 uL) in 5% milk in 
TBST (10 mL), for 1 hour at room temperature. All four were washed the same way in 1X 
TBST, again. Next, the membranes were treated with a chemiluminescent developing solution (2 
mL/blot) for 5 minutes and developed using ImageLab software, for 10 minutes, to create an 
image.  
   
Caveolin Interaction Motif Mimetic Peptides 
Peptide Pretreatment  
 The protocol for the Caveolin Interaction Motif mimetic peptides experiment is identical 
to the protocol described above for the general hormone treatments, except for the addition of the 
peptides to the cells before the protocol began. Four T75’s of HEK293R cells were used. Two 
were designated to receive wild type peptide and two to receive mutant peptide. The peptides 
were added to the correct T75’s at the first step of the protocol, when the growth media is 
removed and changed to serum free media (5 mL) for an hour before the hormone treatment. 0.2 
mM concentration of each peptide, in serum free media, was used.  
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RESULTS 
Time Dependent Hormone Treatment  
Time dependent hormone treatments with urinary hFSH on HEK293R cells showed 
changes in lipid raft residency of hFSHR across time points. Cells were exposed to hFSH for 0, 
5, 15, or 30 minutes. Using western blot analysis, it can be observed that the density of receptor, 
or darkness of bands, changes across the time points in each fraction. Fractions are divided by 
the breaking down of sucrose gradients. Fraction 1 corresponds to the least dense components of 
the plasma membrane. Lipid rafts are assumed to be present across fractions 1, 2, and 3. 
Therefore, based on this set of blots, it can be suggested that hFSHR lipid raft residency changes 
with exposure to hormone in a time dependent manner. (Figure 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Figure 5. hFSHR presence and residency in sucrose gradient fractions 
after varying exposure to hFSH. Detected with 105, an anti-hFSHR 
monoclonal antibody.   
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Caveolin Interaction Motif Mimetic Peptides  
Pretreatment with wild type Caveolin Interaction Motif mimetic peptide showed 
alterations in hFSHR lipid raft residency in the presence of hFSH. Pretreatment with mutant CIM 
peptide did not appear to alter hFSHR raft residency. Cells were treated with either wild type or 
mutant CIM peptide before exposure to hFSH. The samples were broken down into 12 fractions, 
with lipid raft fractions expected to be within fractions 2, 3, 4, 5, and 6. (Figure 6) 
The cells treated with wild type peptide appear to have a higher concentration of hFSHR, 
darker bands, in lipid raft fractions after exposure to hFSH. Treatment with hormone appears to 
have affected receptor residency. Cells treated with mutant peptide do not appear to have any 
change in the concentration of hFSHR in the lipid raft fractions after exposure to hFSH. 
Hormone treatment does not appear to affect residency in this case. (Figure 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
	
Figure 6. hFSHR presence and residency in sucrose gradient fractions 
after exposure to CIM peptide. Detected with 105, an anti-hFSHR 
monoclonal antibody. (Exposure to hFSH = 5 minutes) 
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DISCUSSION  
 The time dependent hormone treatment of hFSH on HEK293-hFSHR expressing cells 
showed alterations in hFSHR lipid raft residency in each exposure time condition (0, 5, 15, 30 
minutes). With no exposure to hFSH, 0-minute condition, the hFSHR bands in the raft fractions 
(lanes 1, 2, 3) are visible but very faint. In the non-raft fractions, especially the heavy fractions, 
the hFSHR bands are significantly darker, indicating a higher concentration of hFSHR in the 
heavier (more dense) gradient fractions. This suggests that without exposure to hormone most 
hFSHRs reside outside of lipid rafts.  
 The residency pattern of hFSHR appears to change with exposure to hormone. After 5 
minutes of exposure to hFSH, the hFSHR bands in lanes 1, 2, and 3 (lipid raft fractions) are 
much darker than the corresponding bands in 0 minutes hFSH exposure. The bands in the heavy, 
non-raft, lanes are still similarly dark after 5 minutes of exposure when compared to 0 minutes 
exposure. This suggests that after 5 minutes of exposure to hFSH, a significant alteration in 
hFSHR residency occurs. HFSHRs appear to be moving into the raft after 5 minutes of exposure 
to hormone.  
 The residency pattern of hFSHR continues to change with longer exposure to hFSH. At 
15 minutes of exposure, the bands in lanes 1, 2, and 3 are still dark just like in the condition of 5 
minutes of exposure. However, the heavy, non-raft, lanes have much lighter hFSHR bands than 
in any prior exposure condition. This further suggests that with increased exposure to hormone, 
more hFSHRs migrate into lipid raft domains.  
 The final time condition is 30 minutes of exposure to hFSH. At this point the hFSHR 
bands are almost identical across all lanes, meaning similar concentrations of hFSHR in each 
gradient fraction. Lanes 1 and 2, and 7 and 8, appear to be the darkest, or highest concentrations. 
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This either means that hFSHRs are migrating back out of the rafts or receptor recycling is 
occurring. The latter is more likely. We believe that most receptors are altering their residency 
within the membrane by migrating into lipid rafts after exposure to hormone. But from there we 
believe they could be getting internalized inside the cells. The dark bands in corresponding non-
raft lanes would be new receptors coming to the surface, as part of the receptor cycling model. 
The other option suggesting that those bands represent the same receptors that originally resided 
out of the raft, moved into the raft after exposure to hormone, then migrated back out, is more 
unlikely.  
 Based on our results, we believe the residency pattern of hFSHR is dependent on 
exposure to hormone, hFSH. Our proposed model suggests that without any hormone present 
most, but not all, hFSHRs reside outside lipid rafts. Once hFSH is present, the receptor appears 
to be moving into the lipid raft domains. The purpose and mechanism for the alteration of 
residency is unknown. The changes in receptor residency also do not appear to end one it 
associates with the raft. We believe the activated receptor goes to the raft to stop signaling and be 
internalized into the cell. This contradicts previous assumptions that the raft enabled or increased 
signal transduction pathways. However, these experiments looked only at the structure and 
function side of receptor residency. Further investigation is needed to link alterations in 
residency with changes in signaling.  
 hFSHR is known to interact with the membrane protein caveolin. It has also been 
demonstrated in the Cohen Laboratory at Union College that mimetic peptides of the caveolin 
interaction motif (CIM) alter hFSHR downstream signaling. Due to these known interactions we 
decided to further investigate the structure and function aspect of the interaction between 
caveolin and hFSHR. The wild type CIM peptide is identical to the 10 amino acid CIM in the 
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fourth transmembrane region of hFSHR. This is the part of hFSHR that is believed to physically 
interact with caveolin. We hypothesized that this wild type peptide will have some unknown 
effect on receptor residency due to its ability to interact with caveolin. Exogenous CIM peptide 
could interact with Caveolin and therefore reduced the frequency of caveolin interacting with 
hFSHR, and possibly have some 
effect on residency. The mutant 
CIM peptide has been mutated at 
each phenylalanine to a leucine.  
  The hormone treatments 
were conducted on the same cell line, HEK293 FSHR, with the same protocol, only changing to 
add a pretreatment exposure to wild type (WT) or mutant (Mut) CIM peptide. The results of this 
experiment show that caveolin does effect receptor raft residency. In the presence of the WT 
peptide and no exposure to hFSH, some hFSHR bands were evident in the raft fractions and 
outside of the raft fractions. With the addition of exposure to hFSH, the darkness of the bands 
and therefore concentration of hFSHR in the raft fractions drastically increases. In the presence 
of the Mut peptide and no exposure to hFSH, hFSHR bands are very similar across all lanes. The 
addition of hFSH to the Mut peptide condition does not change the hFSH residency pattern at all. 
The two Mut blots appear to be the same or extremely similar. Because a large difference 
occurred between WT (- FSH) and WT (+ FSH) and no difference is evident between Mut (- 
FSH) and Mut (+ FSH) it can be observed that the interaction between caveolin and hFSHR has 
effects raft residency. The extent of and mechanism through which it occurs is unknown.  
 We have observed previously that caveolin alters signaling, through experiments with the 
CIM peptide and downstream signaling molecules (Cohen Lab, Angelina Stewart). We have also 
Figure 7.  The wild type and mutant CIM mimetic 
peptide amino acid sequences. 
Tat (Blue)-Wild Type Caveolin Interaction Motif (green) 
YGRKKRRQRRRFAFAAALFPIF 
YGRKKRRQRRRLALAAALLPIL 
Tat (Blue)-Mutant Caveolin Interaction Motif (red) 
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observed that receptor residency is physically dependent on hormone in a time dependent 
manner. It would be very interesting to further evaluate how signaling changes as receptor 
residency changes. We also observed that receptor residency is also caveolin dependent and 
therefore it would be necessary to further investigate how this is occurring and how it relates to 
the effects caveolin also has on signaling. Relating the effects of hFSH and caveolin on receptor 
residency and signaling will give a clear picture to the function and importance of residency to 
the hFSHR signal transduction pathway. Further understanding of the structural and functional 
relationship of the receptor and any downstream signaling controls creates more opportunities to 
modulate the signal transduction pathway through the receptor rather than the hormone. Control 
through the receptor, without, the use of exogenous hormone allows for the pursuit of non-
hormonal interventions for therapeutics like contraceptives.  
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